Drug Search Results
More Filters [+]

Tozadenant

Alternative Names: tozadenant, syn115
Latest Update: 2022-04-22
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: ADORA2 Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Acorda
Company Location: ARDSLEY NY 10502
Company CEO: Ron Cohen
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tozadenant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Parkinson's Disease

Phase 1: Healthy Volunteers|Cocaine-Related Disorders|Hepatic Insufficiency|Liver Failure

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2016-003961-25

P3

Terminated

Parkinson's Disease

2020-06-30

TOZ-PD

P3

Completed

Parkinson's Disease

2019-04-29

TOZ-CL06

P3

Terminated

Parkinson's Disease

2018-01-16

TOZ-PD

P3

Terminated

Parkinson's Disease

2018-01-12

Recent News Events